45 WIGGINS AVENUE, BEDFORD, MA
Stoke Therapeutics Dismisses KPMG as Independent Auditor
CEO Bonus Approval - Ian F. Smith Granted $697,125 Discretionary Bonus
Material disclosure
Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
Stoke Therapeutics and Biogen Showcase Zorevunersen's Potential at AES 2025
Financial Results, Press Release
News, Material Contracts
Amended material disclosure
FY 2025
Q3
Q2
Q1
FY 2024
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Direct Registration System
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload